AbbVie is also developing oncology therapies beyond ADC. A key candidate in the company’s pipeline is etentamig/ABBV-383, a ...

AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...

OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the ...

AstraZeneca PLC (NASDAQ:AZN) operates across global healthcare markets through advanced research pathways, biopharmaceutical ...

XG (XG) member COCONA marked her 20th birthday with a meaningful confession. On the 6th, COCONA revealed on XG's official SNS that she is 'AFAB Transmasculine non-binary' (AFAB transmasculine ...

Imfinzi is the first perioperative immunotherapy approved for resectable gastric/GEJ cancers, offering a new treatment ...

The U.S. Food and Drug Administration has approved Imfinzi (durvalumab) in combination with standard-of-care FLOT ...

FADU unveils Gen7 SSD and PMIC push to cut power, speed AI data access FADU targets 100 million IOPS and companion PMICs to cut data center power and latency ...

As the first immunotherapy option in this setting, the approval sets a new standard for resectable early-stage gastric and gastroesophageal junction (GEJ) cancers.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Cambridge: AstraZeneca has announced that its New Drug Application (NDA) for baxdrostat has been accepted for Priority Review ...

British drugmaker AstraZeneca ($AZN), fresh off a record-high stock price, continues to draw interest from U.S. and European ...